Palbociclib (PD-0332991) HCl

Pfizer辉瑞授权 目录号:S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 902.49 现货
RMB 1406.17 现货
RMB 4670.26 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献25篇:

客户使用该产品的11个实验数据:

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

    Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

产品安全说明书

CDK抑制剂选择性比较

生物活性

产品描述 Palbociclib (PD-0332991) HCl是一种高度选择性的CDK4/6抑制剂,无细胞试验中IC50分别为11 nM/16 nM。它对CDK1/2/5,EGFR,FGFR,PDGFR,InsR等没有抑制活性。Phase 3。
特性 PD-0332991作为有应用前景的工具测定CDK激酶是否具有明显的治疗价值。
靶点
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外研究

PD 0332991 对其他蛋白激酶包括EGFR, FGFR, PGFR, IR等没有抑制效果。 PD 0332991作用于Cdk4时是非ATP竞争性抑制剂。PD 0332991抑制MDA-MB-435乳腺癌细胞,IC50为66 nM,是由于Rb 在Ser780的磷酸化作用下降。PD 0332991抑制胸苷合并到Rb阳性的人类乳腺癌,结肠癌 肺癌,及白血病的DNA中,IC50值为4 nM到0.17 μM。PD 0332991作用于Rb阴性细胞没有抑制效果。PD 0332991作用于MDA-MB-453乳腺癌细胞和结肠-205细胞使细胞积累在G1期。[1]PD 0332991也有效作用于骨髓瘤5T33MM细胞,使细胞对Bortezomib敏感。[2]PD 0332991抑制luminalER-阳性和HER2-增强的乳腺癌细胞系,包括MDA-MB-175 ZR-75-30 CAMA-1 MDA-MB-134 HCC-202 UACC-893 等等。在这些细胞系中,PD 0332991增强Tamoxifen和Trastuzumab 的活性。在MCF7抗Tamoxifen细胞中,PD 0332991也增强tamoxifen 的敏感性。[3] 最新研究显示PD 0332991可以抑制恶性横纹肌样肿瘤(MRT)细胞系包括MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS,且MRT细胞系对PD 0332991敏感性和p16表达呈负相关。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M3n5ZWtqdmG|ZTDBd5NigQ>? M1nI[|I1KGh? NXnwdJdiUW6qaXLpeIlwdiCxZjDDSGs1KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2= NF;tUokzPDZ2MUGwNy=>
COLO205 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi3NkBp NV2yWZZXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1? Ml[2NlQ3PDFzMEO=
U937 MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS3NkBp MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M3mxVVI1PjRzMUCz
MOLM13 NWm0T4x4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGwenRLPzJiaB?= NXns[It5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MWGyOFY1OTFyMx?=
MOLM13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfsO|IhcA>? MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO MYqyOFY1OTFyMx?=
MDA-MB-435 M2TCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr1cXR{OjRiaB?= NX:weWM1UUN3ME2wMlE3KM7:TR?= NX6xbYVHOTV6MEG4N|E>
K562 NECxfI1EgXSxdH;4bYMhSXO|YYm= MnGyPVYhcA>? NYPISpZPTE2VTx?= M2HQcWlEPTB;MjFOwG0> NF60PGYzPDRzN{W2Oi=>
DU145 NFf0U5BEgXSxdH;4bYMhSXO|YYm= NU\lV25oQTZiaB?= NYnsbpZbTE2VTx?= MmDUTWM2OD15LkWg{txO MnvvNlQ1OTd3Nk[=
MDA-MB-231 NIHaPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr0PG1sOSEQvF2= MlPPNlQhcA>? MV;EUXNQ NX7YXIlvS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm NHrGS4kzPDRzN{W2Oi=>
MCF7 M4njVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqxJO69VQ>? MmXVNlQhcA>? MUDEUXNQ M3XoZWNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> MkHRNlQ1OTd3Nk[=
MCF7 MnnyT4lv[XOnIFHzd4F6 M4LGUVUh|ryP NHP2W2MzPCCq MlfESG1UVw>? M{jlcWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NIH4ZokzPDRzN{W2Oi=>
MDA-MB-231 NVvyUWlzU2mwYYPlJGF{e2G7 MXG1JO69VQ>? NYDBO2VYOjRiaB?= Mm\LSG1UVw>? M3nS[mlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NVLLbZFmOjR2MUe1OlY>
MDA-MB-231 NIHWPJZHfW6ldHnvckBCe3OjeR?= MlzNNU0yOCEQvF2= NX\PUVNNOjRiaB?= M3TDWmROW09? MkHo[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen M4PrXlI1PDF5NU[2
MCF7 MmLsSpVv[3Srb36gRZN{[Xl? MX6xMVExKM7:TR?= MU[yOEBp NES2cGtFVVOR M4XlcYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= M1HBRlI1PDF5NU[2
MDA-MB-231 NYfHNJpyTnWwY4Tpc44hSXO|YYm= NVGxXGQ1OC53LUGg{txO MlnSOFghcA>? M2juTmROW09? Mo[3bIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> MnzRNlQ1OTd3Nk[=
MCF7 M2rCTGZ2dmO2aX;uJGF{e2G7 M3TPSFAvPS1zIN88US=> M4fJVFQ5KGh? NFTZVG9FVVOR NXK2bpY1cGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? MXmyOFQyPzV4Nh?=
697 NXXIcnYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTtTWM2OD1zNEiuN|ghdk1? NXvOfpk5W0GQR1XS
P12-ICHIKAWA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTl4LkC0JI5O NEHCU3dUSU6JRWK=
NB69 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYiweIt1UUN3ME2xOlEvQCCwTR?= NYHEcIdTW0GQR1XS
EoL-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD5eZVKSzVyPUG4O{4zPiCwTR?= NU\Yd4RkW0GQR1XS
BHT-101 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHBdoFrUUN3ME2xPVgvOjVibl2= M2q3dHNCVkeHUh?=
SK-NEP-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfFTWM2OD1{MkCuNFIhdk1? MXvTRW5ITVJ?
MHH-NB-11 NEHKRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jyPWlEPTB;MkKwMlE6KG6P MV3TRW5ITVJ?
AsPC-1 NYHLV3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnCNZE3UUN3ME2yOVIvPTNibl2= NHS2NJFUSU6JRWK=
ES1 NGOySY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ3Nj6yOUBvVQ>? M2O1UHNCVkeHUh?=
LAMA-84 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ta[2lEPTB;MkW4MlE6KG6P MkLoV2FPT0WU
MOLT-16 NF7qeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNNpYyUUN3ME2yOVgvPDlibl2= NHTCZ|RUSU6JRWK=
ES7 M4K5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LVV2lEPTB;MkezMlA6KG6P MV3TRW5ITVJ?
KY821 M{XZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjLb|c5UUN3ME2zNVQvOSCwTR?= MXrTRW5ITVJ?
RT-112 NFLaTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN{MT6wOUBvVQ>? NX;qeGFFW0GQR1XS
HL-60 NFS4RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN2MD62OkBvVQ>? MVHTRW5ITVJ?
MOLT-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTVS3BkUUN3ME2zOFUvOTNibl2= M{LBdnNCVkeHUh?=
KARPAS-45 NUTkTlVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTN5Nj6xOkBvVQ>? NGXrcm5USU6JRWK=
SK-N-AS MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN6Nz64N{BvVQ>? M4fQVXNCVkeHUh?=
CTB-1 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJTWM2OD12MEWuNFIhdk1? MmjXV2FPT0WU
NKM-1 NHvPbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj6dm1uUUN3ME20NVEvQDlibl2= NUPBR4lmW0GQR1XS
HTC-C3 NECy[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPCNIhKSzVyPUSzNk46PSCwTR?= MkHJV2FPT0WU
BE-13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR2ND6yO{BvVQ>? MYjTRW5ITVJ?
KOSC-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXZTWM2OD12Nk[uPUBvVQ>? M1PxSnNCVkeHUh?=
NB14 NGLxUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR6Mz61PEBvVQ>? MVnTRW5ITVJ?
CAL-27 M2TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLs[3RKSzVyPUS5OE42QSCwTR?= NUnKN2E3W0GQR1XS
H9 M4r4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTR7NT60N{BvVQ>? MUXTRW5ITVJ?
RS4-11 NG[xUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVyND63N{BvVQ>? M33lc3NCVkeHUh?=
PA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPJTWM2OD13MEmuPFYhdk1? MVrTRW5ITVJ?
MV-4-11 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PHUmlEPTB;NUGzMlg2KG6P NXzVbmo6W0GQR1XS
OS-RC-2 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHrTWM2OD13MkGuOlIhdk1? M1ywNXNCVkeHUh?=
RPMI-8226 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTV{Nj64OkBvVQ>? M4nwRnNCVkeHUh?=
HGC-27 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTV4ND65PUBvVQ>? NVvuOYhxW0GQR1XS
CHP-212 NELqeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG1NFVXUUN3ME21PVMvPTlibl2= M1HjdHNCVkeHUh?=
NB10 NVW0NJRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jHSmlEPTB;NUm5MlE5KG6P NV7KcY9UW0GQR1XS
HH MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL6TWM2OD13OUmuOFMhdk1? M3riUHNCVkeHUh?=
EW-16 NYXCNWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXzNmJKSzVyPU[wN{42OiCwTR?= NF\BOJlUSU6JRWK=
ES8 NWf0VIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZyNT6yNUBvVQ>? NX20dVllW0GQR1XS
HAL-01 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQWppbUUN3ME22NFUvPjdibl2= MojBV2FPT0WU
A204 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XjPWlEPTB;NkOzMlkyKG6P MVzTRW5ITVJ?
MHH-PREB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTZ|Nj65PUBvVQ>? NW\lV5VjW0GQR1XS
EM-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZ3MD62OEBvVQ>? M{jSR3NCVkeHUh?=
BV-173 NVja[3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZ3Mj60PEBvVQ>? M1LKd3NCVkeHUh?=
ONS-76 NHvBU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZ5Nz64NkBvVQ>? MVPTRW5ITVJ?
KM-H2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn2[XJKSzVyPU[5OU42PCCwTR?= Mn7QV2FPT0WU
D-263MG M2judGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr5dFdKSzVyPUexO{4yOiCwTR?= MmqzV2FPT0WU
ES3 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfUe5JKSzVyPUeyPE46OyCwTR?= MUjTRW5ITVJ?
VA-ES-BJ NGPIW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTd|Mj6yO{BvVQ>? NIfDVWhUSU6JRWK=
NBsusSR MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XNdmlEPTB;N{SyMlk6KG6P NHzYRYNUSU6JRWK=
NCI-H520 M3vWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf3S5VKSzVyPUe0Ok42OiCwTR?= NIHZbGZUSU6JRWK=
ES5 NVewOGN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTd3Mj64JI5O MnPLV2FPT0WU
T-24 NXf4O2xsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTd5OD63NUBvVQ>? MWLTRW5ITVJ?
SW962 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRThyOD62N{BvVQ>? MVjTRW5ITVJ?
EW-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD16MEiuO|Yhdk1? M1zhOnNCVkeHUh?=
RXF393 NULZOFR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NED5PWVKSzVyPUixNk44QSCwTR?= M4rp[XNCVkeHUh?=
U251 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThzMz64PEBvVQ>? Ml;2V2FPT0WU
CAMA-1 M4XBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTh|Mz65OEBvVQ>? MmT1V2FPT0WU
JVM-3 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;3TWM2OD16NUGuO|ghdk1? NH3l[|JUSU6JRWK=
COLO-800 NI\KTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUCzS5V3UUN3ME24PVcvPzhibl2= NETBV49USU6JRWK=
OVCAR-5 MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTlyMD6xJI5O Mki5V2FPT0WU
LB1047-RCC MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTl{Nz61OkBvVQ>? MUTTRW5ITVJ?
SW954 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHju[JNKSzVyPUmyPU41OSCwTR?= NYruNHhTW0GQR1XS
J-RT3-T3-5 NWTFbI1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hl[GlEPTB;OUO2MlA3KG6P NWDMfWxDW0GQR1XS
Mewo M{DiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXHWohtUUN3ME25N|YvPiCwTR?= M1XmN3NCVkeHUh?=
NCI-H1770 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPsfodKSzVyPUm0NE42PSCwTR?= M17MU3NCVkeHUh?=
HO-1-N-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJcWtKSzVyPUm2Nk45OSCwTR?= NGTFOXNUSU6JRWK=
HSC-3 M2fV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknWTWM2OD17Nk[uOFghdk1? NXHqN3V2W0GQR1XS
TYK-nu Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDrTWM2OD17OUiuNlUhdk1? NHTrXo5USU6JRWK=
KYSE-150 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELVdZRKSzVyPUGuNFAxPzZizszN MorVV2FPT0WU
SN12C MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXFTWM2OD1zLkCwPFc2KM7:TR?= MmX2V2FPT0WU
MOLT-13 M4ThWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMEG0NlEh|ryP M17rSXNCVkeHUh?=
TE-11 NYD0U2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvSTWM2OD1zLkC0PFEzKM7:TR?= NWDpZmF4W0GQR1XS
DB M362cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXIS4ZKSzVyPUGuNFczPzNizszN NVewVYRxW0GQR1XS
CAL-39 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonJTWM2OD1zLkC3OVIzKM7:TR?= NIP4T2JUSU6JRWK=
A3-KAW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXETWM2OD1zLkC4OFA5KM7:TR?= NUTVTFZrW0GQR1XS
CHP-134 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMUG4NFch|ryP M3zv[3NCVkeHUh?=
TGW NFrTcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjJTWM2OD1zLkGyN|k2KM7:TR?= NYjEcodXW0GQR1XS
QIMR-WIL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PSPWlEPTB;MT6xN|E{PCEQvF2= NWfyTZB4W0GQR1XS
NCI-SNU-1 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwMU[zOVQh|ryP NYnPWpFjW0GQR1XS
CGTH-W-1 NHLBZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFztRYFKSzVyPUGuNVcyQDZizszN NWjoRWx[W0GQR1XS
MHH-ES-1 M1jMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfqTWM2OD1zLkG3PVg3KM7:TR?= MX\TRW5ITVJ?
LB2241-RCC NFyzUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LvOmlEPTB;MT6xPFYzKM7:TR?= M3nnTnNCVkeHUh?=
ML-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvhcYlVUUN3ME2xMlIxPzN2IN88US=> M{ewNHNCVkeHUh?=
COR-L23 M2\LVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxTJZKSzVyPUGuNlI6OzNizszN NYfUW|JYW0GQR1XS
BFTC-905 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC1OHZ5UUN3ME2xMlI1OjZ5IN88US=> NWLJV5A3W0GQR1XS
Hs-578-T NX62WYdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwMkW4NVch|ryP M4jYcnNCVkeHUh?=
KG-1 M3rpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f0WWlEPTB;MT6yOlY5PiEQvF2= MknIV2FPT0WU
HEL NUTaUlczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\1d4U5UUN3ME2xMlI6OzN6IN88US=> M33r[3NCVkeHUh?=
A549 NV[0WphyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrTeml3UUN3ME2xMlI6Ozl7IN88US=> MorqV2FPT0WU
COLO-741 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILwfldKSzVyPUGuN|IxQDlizszN MnfCV2FPT0WU
PC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojzTWM2OD1zLkO1NlIyKM7:TR?= MY\TRW5ITVJ?
HOS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\VUZlvUUN3ME2xMlM2Ojl4IN88US=> NX3TbVBzW0GQR1XS
HT-1080 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwM{e1NVkh|ryP M2rQdnNCVkeHUh?=
TE-8 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwNEG3O|Qh|ryP M13PW3NCVkeHUh?=
BHY M2ntTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\pXWlEPTB;MT60OlkzOyEQvF2= M4nrOHNCVkeHUh?=
BB65-RCC NG\OOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD0PHZ2UUN3ME2xMlUxPTJ6IN88US=> MUHTRW5ITVJ?
HN MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TuTGlEPTB;MT61OFA4OSEQvF2= NIGwUotUSU6JRWK=
NCI-H441 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXqPJQzUUN3ME2xMlU1QTB5IN88US=> NYPxbXRoW0GQR1XS
RPMI-8866 NHu5d|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLoS2JKSzVyPUGuOVg2ODdizszN NY\nZ3RYW0GQR1XS
CAL-62 NX6yWXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;xb2lEPTB;MT62NFg3OiEQvF2= NYP5UW92W0GQR1XS
MG-63 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfGfJlKSzVyPUGuOlE5OTNizszN MoLZV2FPT0WU
SK-LU-1 NXHtcYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LNO2lEPTB;MT62NlE2OiEQvF2= M{O3[3NCVkeHUh?=
BCPAP NULUTHpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq5TWM2OD1zLk[2OFU4KM7:TR?= MoH5V2FPT0WU
22RV1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfuOWJ[UUN3ME2xMlY4QDR|IN88US=> MYjTRW5ITVJ?
T47D NVvGZpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwNkiwOlEh|ryP NVmxcIo2W0GQR1XS
MSTO-211H M{PjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNkm2NFMh|ryP M4[xS3NCVkeHUh?=
DEL M3HTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H5ZmlEPTB;MT63NFI4OyEQvF2= MkTwV2FPT0WU
H4 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTZPFJJUUN3ME2xMlc{OjF{IN88US=> NYjKepNWW0GQR1XS
CAL-51 M3PxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwN{S4OVUh|ryP MY\TRW5ITVJ?
ABC-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF24[HFKSzVyPUGuO|g2QDJizszN NH7GT2FUSU6JRWK=
MZ2-MEL M3vjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfGdXkxUUN3ME2xMlc6PTR{IN88US=> M17aV3NCVkeHUh?=
YKG-1 NYm4NGJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHJTWM2OD1zLkixNFYyKM7:TR?= NU\iVYhbW0GQR1XS
KM12 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDFe3dKSzVyPUGuPFE3ODJizszN Mn3SV2FPT0WU
L-363 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHPdG1mUUN3ME2xMlg4PDF{IN88US=> NIC3RYNUSU6JRWK=
KU812 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO0TWM2OD1zLki5NlgzKM7:TR?= MVrTRW5ITVJ?
LOXIMVI NWTUWmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4TWM2OD1zLkmxNlI5KM7:TR?= M{TE[XNCVkeHUh?=
G-401 M2myVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XOSGlEPTB;MT65NlQzQCEQvF2= NIHxZ2pUSU6JRWK=
SW780 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLZTWM2OD1zLkm2NlQ3KM7:TR?= M4PkdnNCVkeHUh?=
SW872 NH7JOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPKTVFKSzVyPUGuPVg{OyEQvF2= MlvQV2FPT0WU
NB7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLVTWM2OD1zLkm5N|I{KM7:TR?= MW\TRW5ITVJ?
T98G MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwMEC2OlYh|ryP MX7TRW5ITVJ?
SW1710 Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr4ZolKSzVyPUKuNFY6PDVizszN NV\aW5ZxW0GQR1XS
NCI-H1573 NFjFVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrHNmFZUUN3ME2yMlA4Ojl6IN88US=> MXPTRW5ITVJ?
KE-37 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwT5dKSzVyPUKuNFg6PTFizszN MXXTRW5ITVJ?
786-0 NG\P[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxOGlEPTB;Mj6xOVQ{QSEQvF2= MVzTRW5ITVJ?
SAS M4LpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPLVllrUUN3ME2yMlIxOzd2IN88US=> NV6zW5pHW0GQR1XS
CAL-54 M37YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PSXGlEPTB;Mj6yNFQyOyEQvF2= NVz3SYk6W0GQR1XS
SF268 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT4TWM2OD1{LkKzNVIzKM7:TR?= NWXjW5g1W0GQR1XS
SW620 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvzcmVVUUN3ME2yMlI3OTZ7IN88US=> NUnHflY{W0GQR1XS
MN-60 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnDfJRZUUN3ME2yMlMyODZizszN Moq2V2FPT0WU
EFO-27 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn65TWM2OD1{LkOyNFU5KM7:TR?= MoTFV2FPT0WU
NCI-H747 M13sUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwM{KxPVkh|ryP NGGzb5NUSU6JRWK=
HCC2218 NIDoeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXY[5IyUUN3ME2yMlM2Ozd2IN88US=> M2T3UXNCVkeHUh?=
MIA-PaCa-2 NUTv[mxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwM{[0N|ch|ryP Mo\VV2FPT0WU
SJSA-1 NXzDbWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\TVmlEPTB;Mj6zO|c6PiEQvF2= NVzYfpZWW0GQR1XS
RKO NEX2UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXBTWM2OD1{LkO4OFk3KM7:TR?= MXfTRW5ITVJ?
NB6 M1TCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwNECzO|Qh|ryP NGX5ZndUSU6JRWK=
ES4 NGH2RXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJwNEW0NlIh|ryP MlHXV2FPT0WU
EGI-1 NFjzcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCwTWM2OD1{LkS2PFg{KM7:TR?= MVPTRW5ITVJ?
CTV-1 M{\FT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPrOm1KSzVyPUKuOVI4PzNizszN NFj0NWZUSU6JRWK=
NCI-H1355 NG[wd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7lOI1KSzVyPUKuOVU6PTFizszN NEDxS|NUSU6JRWK=
GT3TKB NVnjSoh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH5TWM2OD1{LkW5NVk6KM7:TR?= M3\GXHNCVkeHUh?=
SK-HEP-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XUmlEPTB;Mj61PVI3PiEQvF2= MV7TRW5ITVJ?
GAMG NX6xSWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDwO5dzUUN3ME2yMlU6Ozl2IN88US=> MXPTRW5ITVJ?
SK-MES-1 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwNkG4NFMh|ryP NWrNOFFwW0GQR1XS
RO82-W-1 M4DXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHMdpJ2UUN3ME2yMlYzODV5IN88US=> M2\GUnNCVkeHUh?=
ECC10 NEnoS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwN{CyNFYh|ryP MYLTRW5ITVJ?
MCF7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j3UmlEPTB;Mj63NVQ3PCEQvF2= MoDxV2FPT0WU
D-283MED M{fYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrHXo1KSzVyPUKuO|I1OyEQvF2= NYfX[2RSW0GQR1XS
RPMI-7951 NE\P[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXCZ5pKSzVyPUKuO|U3QTRizszN MniwV2FPT0WU
Ramos-2G6-4C10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLuTWM2OD1{Lke3NFk6KM7:TR?= NWe3THptW0GQR1XS
KGN MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS4NGg3UUN3ME2yMlgyQDh2IN88US=> M1nxT3NCVkeHUh?=
NUGC-3 M4K2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTHTWM2OD1{LkiyOVA2KM7:TR?= MofRV2FPT0WU
NCI-H292 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLFTWM2OD1{Lki1NFU{KM7:TR?= M2j6eHNCVkeHUh?=
Becker M13zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfHeVNKSzVyPUKuPVU5OzJizszN M376T3NCVkeHUh?=
NCI-H1299 NYrFV5J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fvNGlEPTB;Mz6wOVI3OyEQvF2= MWDTRW5ITVJ?
ETK-1 NYP1ZWtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHVPIhKSzVyPUOuNFU1OyEQvF2= NF\hU5VUSU6JRWK=
TK10 NVjOb3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNwMkCxOlUh|ryP NGrv[olUSU6JRWK=
VMRC-RCZ NInUXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLpXYM2UUN3ME2zMlM3PDh6IN88US=> Mmf1V2FPT0WU
YH-13 NGrjdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lhd2lEPTB;Mz60OFA4QSEQvF2= MmDHV2FPT0WU
DU-145 M1zUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnkW|ZKSzVyPUOuOFYzPjlizszN NELaXlhUSU6JRWK=
SW1088 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj4dHptUUN3ME2zMlQ4PDdizszN NYS2SJBOW0GQR1XS
HOP-92 NHTpb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjtZ5hKSzVyPUOuOVA{PDJizszN NUHlfY1EW0GQR1XS
KP-N-YS MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fMUmlEPTB;Mz62NlE{QSEQvF2= Moj6V2FPT0WU
NCI-H460 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTSTWM2OD1|Lk[2O|Mh|ryP M3;UbXNCVkeHUh?=
U-2-OS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1Wm5CUUN3ME2zMlczPTN3IN88US=> MnzzV2FPT0WU
A101D NUfKSZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwN{[5N|Yh|ryP Mk\LV2FPT0WU
MDA-MB-231 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH3TWM2OD1|LkixPVUyKM7:TR?= NFTvSVFUSU6JRWK=
IST-MES1 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITjTXRKSzVyPUOuPFMzKM7:TR?= MmHRV2FPT0WU
COR-L105 NWLX[ldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwMEG4JO69VQ>? MYjTRW5ITVJ?
NCI-H1437 NUnzbZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj3TWM2OD12LkCyN|AzKM7:TR?= MVHTRW5ITVJ?
CAL-85-1 M3iwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK4enV[UUN3ME20MlAzPDZzIN88US=> NWP3V|NSW0GQR1XS
MZ1-PC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XaVmlEPTB;ND6xPFU2PiEQvF2= NEXzV|dUSU6JRWK=
VM-CUB-1 NVrmNFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\MOWlEPTB;ND6zNVI5PCEQvF2= MnrsV2FPT0WU
CHL-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwM{KxOlkh|ryP M{GxPHNCVkeHUh?=
MDA-MB-361 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\uTWM2OD12LkOzNVU{KM7:TR?= MVLTRW5ITVJ?
NCI-H661 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnoPWd2UUN3ME20MlUxODl{IN88US=> MoPwV2FPT0WU
EW-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvLWW5KSzVyPUSuOVIzOzFizszN MVnTRW5ITVJ?
BEN Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf0PXdKSzVyPUSuOVI5OTVizszN NVm0OllUW0GQR1XS
BFTC-909 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPuTWM2OD12LkW2Nlc2KM7:TR?= MkLEV2FPT0WU
NCI-H2087 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRfmZKSzVyPUSuOVgyPjRizszN M{XsRXNCVkeHUh?=
RVH-421 M4rWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\mTWM2OD12Lk[2Olkh|ryP NYjr[4NnW0GQR1XS
P30-OHK NV3DUJhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vmXWlEPTB;ND62PFAxQCEQvF2= MWrTRW5ITVJ?
NCI-H28 NFP2SXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTRwOEG2OlEh|ryP NFvqXplUSU6JRWK=
ES6 NWrQUIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;Ld21KSzVyPUSuPFMxOTZizszN NEPjUHVUSU6JRWK=
769-P NFfESm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRwOEW5NlYh|ryP NGC4T4VUSU6JRWK=
OE33 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXuTWM2OD12Lki4NVYyKM7:TR?= MlzDV2FPT0WU
SW982 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwOUWwOlEh|ryP NVGxSFZRW0GQR1XS
A388 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTOTWM2OD13LkCyPVg{KM7:TR?= NV;2VWR3W0GQR1XS
TI-73 NUPWW4RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXTR2hKSzVyPUWuNFYyQTRizszN NGO5cHpUSU6JRWK=
HCT-116 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDSTWM2OD13LkC5PFg6KM7:TR?= NXXOenZRW0GQR1XS
HuP-T3 NYTNfZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\wTWM2OD13LkG4O|A6KM7:TR?= MkLGV2FPT0WU
G-402 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLic5dRUUN3ME21MlE6PDF4IN88US=> MkDEV2FPT0WU
NCI-H1792 NILVfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjUZoxvUUN3ME21MlI1PjJ{IN88US=> NID4VoJUSU6JRWK=
NCI-H209 NX3rUIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTVwMkW5OFIh|ryP M1\pNHNCVkeHUh?=
NCI-H1650 M3;vOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojPTWM2OD13LkOwOlM1KM7:TR?= M1vI[nNCVkeHUh?=
LCLC-97TM1 M4XHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm0U3BkUUN3ME21MlMyQDB6IN88US=> MlTuV2FPT0WU
S-117 NHXtVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwM{[5O|Yh|ryP MYDTRW5ITVJ?
GI-ME-N NW\kOWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXMTWM2OD13LkO5OlgyKM7:TR?= MVnTRW5ITVJ?
NCI-H2122 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTVwNEmzPVch|ryP Mom1V2FPT0WU
NCI-H1793 NF7udoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\2N2lEPTB;NT62O|U6OyEQvF2= NIq5O2FUSU6JRWK=
C2BBe1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTNTWM2OD13LkewNFg5KM7:TR?= NViye4o3W0GQR1XS
TE-12 NHfBeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTVwOEC1OVYh|ryP MYfTRW5ITVJ?
LCLC-103H M4G4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS5ZWFKUUN3ME21MlkyPyEQvF2= MX3TRW5ITVJ?
A673 M136Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD13LkmxPVMzKM7:TR?= M3X0UHNCVkeHUh?=
BB30-HNC MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17QdGlEPTB;NT65PFM3KM7:TR?= NFrsNGFUSU6JRWK=
SF295 NV\lPZZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljITWM2OD14LkCwOFIzKM7:TR?= M2HaTHNCVkeHUh?=
KU-19-19 M2TwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZwMEG3N|Eh|ryP MkOyV2FPT0WU
CFPAC-1 NEfMUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0RmxKSzVyPU[uNFQ1PDNizszN NX64NZhsW0GQR1XS
LoVo MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL1cJRKSzVyPU[uNFUxPjNizszN M2jWWnNCVkeHUh?=
8505C NEHkc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3XTWM2OD14LkC3OVc{KM7:TR?= MkTXV2FPT0WU
GMS-10 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZwMUWwNFIh|ryP M32yWnNCVkeHUh?=
Ca9-22 NVjQSGJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZwMU[3NUDPxE1? MVzTRW5ITVJ?
DOK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3Z2lEPTB;Nj6yNlA4OiEQvF2= M1jyXHNCVkeHUh?=
FADU M{\MSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhV|hFUUN3ME22MlI3ODN7IN88US=> MX\TRW5ITVJ?
BxPC-3 NYjmd3YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LCNmlEPTB;Nj6yO|MzKM7:TR?= NXPFOVNMW0GQR1XS
CAL-33 NFSyRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTZwMkmyNFEh|ryP M4nrOHNCVkeHUh?=
SHP-77 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HQcWlEPTB;Nj6zNVUyOiEQvF2= NGrWW21USU6JRWK=
LXF-289 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXrPFFDUUN3ME22MlM{PDV3IN88US=> NGPH[mhUSU6JRWK=
GB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\WVZRkUUN3ME22MlM5OiEQvF2= NEf3WmJUSU6JRWK=
KS-1 NHrYe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTq[FRKSzVyPU[uN|g1PDdizszN Mn\mV2FPT0WU
D-502MG NVn4fINwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO3eZFsUUN3ME22MlQzOzd4IN88US=> NWrjVZB6W0GQR1XS
LAN-6 NUK2RnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv0N3BKSzVyPU[uOVExOjNizszN M4nwUnNCVkeHUh?=
H-EMC-SS NYiwN3BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzDSlNKSzVyPU[uOVYyPDdizszN M3nnfHNCVkeHUh?=
LC-2-ad NXToXIVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn2TWM2OD14Lk[wNFc3KM7:TR?= MlX5V2FPT0WU
NCI-H1693 NYWyO2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHSdlVUUUN3ME22MlYzOjF3IN88US=> MXrTRW5ITVJ?
SK-N-FI M2K5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDVTWM2OD14Lke1NFQ1KM7:TR?= MXTTRW5ITVJ?
D-423MG MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvITpdKSzVyPU[uO|YyOTdizszN M2HHNXNCVkeHUh?=
KNS-42 NWH5U3dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73R|JpUUN3ME22Mlc5OTl5IN88US=> MkPGV2FPT0WU
GCT MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[4OoY{UUN3ME22Mlk{QCEQvF2= MoHKV2FPT0WU
DSH1 NHHKfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Dx[2lEPTB;Nz6wOlM{KM7:TR?= NHHaOmpUSU6JRWK=
D-247MG NYrWb3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tt[GlEPTB;Nz6wO|g5OSEQvF2= NIn6VGJUSU6JRWK=
NCI-SNU-5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS2TWM2OD15LkG4N|cyKM7:TR?= NXTPfZZPW0GQR1XS
TE-6 NH:wcGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWNFVKSzVyPUeuNlA3ODFizszN M1XtSXNCVkeHUh?=
NOMO-1 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nycWlEPTB;Nz6yNlEzPyEQvF2= M3\EWXNCVkeHUh?=
NB17 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XieGlEPTB;Nz6zNFMxQSEQvF2= M3f6S3NCVkeHUh?=
EW-22 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jRXmlEPTB;Nz6zOFM1QCEQvF2= NEfaOlZUSU6JRWK=
EW-13 NEfoS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfDd5JxUUN3ME23MlM2OTZ{IN88US=> M2DoOXNCVkeHUh?=
DOHH-2 NYjkTpRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwNESwNkDPxE1? MUnTRW5ITVJ?
TGBC1TKB NVTSPFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPsPI84UUN3ME23MlQ6QDl7IN88US=> M2rHTHNCVkeHUh?=
GR-ST MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfzXHBKSzVyPUeuOVI2QTRizszN MUjTRW5ITVJ?
KYSE-520 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UNGlEPTB;Nz61OVUyPSEQvF2= NUHiS5lVW0GQR1XS
CAPAN-1 NHezOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDFOWFKSzVyPUeuOVk2OSEQvF2= NGLVTnJUSU6JRWK=
HCE-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXYU3Q3UUN3ME23MlYzOjd7IN88US=> M3fhVHNCVkeHUh?=
MLMA NH\UPIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTofGF1UUN3ME23MlYzQTV5IN88US=> MkfqV2FPT0WU
HT-144 NV7XeJNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTdwNkWzOlgh|ryP M{\iUnNCVkeHUh?=
KYSE-180 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;4dZNKSzVyPUeuO|EyPjlizszN M3T1dnNCVkeHUh?=
TE-5 M1PTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDlTWM2OD15Lkm1PVcyKM7:TR?= M{n4PXNCVkeHUh?=
IGROV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\LVGlEPTB;Nz65PFU2OSEQvF2= MUjTRW5ITVJ?
NCI-H1581 NHvWfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEezPFlKSzVyPUiuNFEzKM7:TR?= NGK0OHVUSU6JRWK=
SW1990 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P1TWlEPTB;OD6wOFY2QSEQvF2= MVjTRW5ITVJ?
EFM-19 NEPSXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXzTWM2OD16LkC4OVQ2KM7:TR?= MnHoV2FPT0WU
OGR-1 M2XkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWzTJVUUUN3ME24MlQ{ODJ|IN88US=> Mk\QV2FPT0WU
U-118-MG NWPBT5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33xN2lEPTB;OD60N|Q3OyEQvF2= MoTOV2FPT0WU
SK-OV-3 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRThwNE[3OlUh|ryP NF2zZYFUSU6JRWK=
KNS-62 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom1TWM2OD16LkWxO|YyKM7:TR?= NWjzSox7W0GQR1XS
GOTO MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRThwNUe2N|Uh|ryP MnewV2FPT0WU
8305C NVXOb49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRThwN{C0PFQh|ryP M4ThNnNCVkeHUh?=
RPMI-2650 NWnS[XdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwN{G5OVUh|ryP MlLVV2FPT0WU
NEC8 NXG1Vlk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDTOlBKSzVyPUiuO|Q{ODdizszN MXPTRW5ITVJ?
KYSE-450 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXtTWM2OD16Lki2OVQ5KM7:TR?= NXKxSnhbW0GQR1XS
RMG-I M2O3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH2TWM2OD17LkG0NFU5KM7:TR?= NW\qVlhZW0GQR1XS
CAKI-1 NEnJ[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\SO21UUUN3ME25MlMyQTd7IN88US=> MYHTRW5ITVJ?
KYSE-510 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4WGlEPTB;OT6zOVc4QCEQvF2= MWLTRW5ITVJ?
A4-Fuk M2rO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1TWM2OD17LkO2O|AyKM7:TR?= NWLxUoJPW0GQR1XS
AN3-CA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTGWWtKSzVyPUmuOFU1PDRizszN NEjBZphUSU6JRWK=
SK-N-DZ MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTlwN{K4OFkh|ryP NH\DV5FUSU6JRWK=
HSC-2 M1zaUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLhV|JKSzVyPUmuO|Y3OjlizszN MV;TRW5ITVJ?
EW-1 Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHkTWM2OD17Lke5N|Y6KM7:TR?= Mmr1V2FPT0WU
D-566MG M3r4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fFOGlEPTB;OT64N|Y3PCEQvF2= M4PjbXNCVkeHUh?=
COLO-792 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3neY5KSzVyPUmuPVg4PDZizszN NUH6cm1IW0GQR1XS
TE-10 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle1TWM2OD1zMD6wN|k3KM7:TR?= M33Zc3NCVkeHUh?=
NCI-H650 M2TsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LEPWlEPTB;MUCuOFI5PiEQvF2= M4ixWnNCVkeHUh?=
U-266 NWDzUJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXmTWM2OD1zMD60OVUh|ryP Mkj6V2FPT0WU
Detroit562 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG3TWM2OD1zMT6wOVE2KM7:TR?= MnvqV2FPT0WU
NH-12 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDEUVhKSzVyPUGxMlE1PDZizszN MX;TRW5ITVJ?
CO-314 M2\BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrQWJdKSzVyPUGxMlI5PDJizszN MWLTRW5ITVJ?
IST-MEL1 M32yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFzLkWzNlMh|ryP M3i5O3NCVkeHUh?=
KNS-81-FD MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFzLkW1Nlch|ryP MnXZV2FPT0WU
SW1463 NFrDPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37QdGlEPTB;MUGuOVk5QSEQvF2= M4TzUnNCVkeHUh?=
NCI-H23 NYrNZ284T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLETWM2OD1zMT62OVUzKM7:TR?= NU\oZ2QyW0GQR1XS
SK-MEL-2 M3L3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ldIdoUUN3ME2xNU44OTl5IN88US=> NGnTco5USU6JRWK=
NB13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljXTWM2OD1zMj6xOFk2KM7:TR?= MWfTRW5ITVJ?
Daoy NEPDWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITD[o1KSzVyPUGyMlI5PTZizszN NWDxZXlOW0GQR1XS
NCI-H1623 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7DTolKSzVyPUGyMlM5ODFizszN M1G2VnNCVkeHUh?=
NMC-G1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF{LkexO{DPxE1? MUfTRW5ITVJ?
DK-MG MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4CxfmlEPTB;MUKuPVQ5OiEQvF2= M3vYUXNCVkeHUh?=
TCCSUP M3LtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF|LkGyPFQh|ryP NFOzXItUSU6JRWK=
SCC-15 NX[0R4lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PXc2lEPTB;MUOuNlY2OSEQvF2= Mny3V2FPT0WU
NOS-1 NHvISWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTlTWM2OD1zMz6yPFk{KM7:TR?= NX3idmZ1W0GQR1XS
RH-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXWTWM2OD1zMz6zNFM4KM7:TR?= NEXaV29USU6JRWK=
SK-MEL-3 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF|LkO3Nlgh|ryP MmLsV2FPT0WU
NB5 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF|LkSwOlch|ryP NHHFbHJUSU6JRWK=
SNU-387 NHjYfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSw[5VLUUN3ME2xN{42ODd{IN88US=> NWfOT5FPW0GQR1XS
CAL-120 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF|Lk[3NVgh|ryP MWDTRW5ITVJ?
Mo-T MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSzTWM2OD1zMz63NFch|ryP MYrTRW5ITVJ?
LNCaP-Clone-FGC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLrOoUzUUN3ME2xN{44QTl{IN88US=> NGDxTodUSU6JRWK=
CAN MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1TZB{UUN3ME2xOE4xOjh6IN88US=> NHe3VYRUSU6JRWK=
SK-MEL-30 M4XvSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrUUGxKSzVyPUG0MlA3OyEQvF2= MXjTRW5ITVJ?
COLO-678 NHz0OXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHWOI9KSzVyPUG0MlA5OjJizszN M4f0W3NCVkeHUh?=
SCC-9 NEC0TpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7CTWM2OD1zND6xNFIyKM7:TR?= MYDTRW5ITVJ?
KINGS-1 NWC0fo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:zXIxnUUN3ME2xOE4yPDB{IN88US=> MVTTRW5ITVJ?
SL-513 NFrSXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrNTWM2OD1zND6xPFch|ryP NFzVUG1USU6JRWK=
HLE M3\Tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLKXGlIUUN3ME2xOE4{QDV{IN88US=> M4rnRXNCVkeHUh?=
SW1573 NFi2cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF2LkS0N|Uh|ryP M2XUTHNCVkeHUh?=
KYSE-140 NUnMRWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXuTWM2OD1zND62N|I4KM7:TR?= Mnv5V2FPT0WU
SK-PN-DW NFX3eG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnoTWM2OD1zND64NFAyKM7:TR?= MXrTRW5ITVJ?
A253 NF6w[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfoWIhKSzVyPUG1MlA3OjVizszN M{OwcHNCVkeHUh?=
CAL-12T Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG5TWM2OD1zNT60OlYzKM7:TR?= MXnTRW5ITVJ?
COLO-679 NELCc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXBTWM2OD1zNT63Olg{KM7:TR?= NXnkfGhDW0GQR1XS
UACC-257 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK0TYxxUUN3ME2xOk4yOjBzIN88US=> MUDTRW5ITVJ?
U-87-MG NYLI[3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD1zNj6zOVI{KM7:TR?= NYHyV5hiW0GQR1XS
HCC1806 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\KNW9uUUN3ME2xOk44ODdzIN88US=> NGrGNItUSU6JRWK=
NCI-H2170 Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW0TWM2OD1zNz6yOFQ5KM7:TR?= Mm\aV2FPT0WU
AGS NX61bnhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[wdGlEPTB;MUeuN|gxQCEQvF2= MVvTRW5ITVJ?
MEL-HO NXfzeWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nGTWlEPTB;MUeuO|UxOyEQvF2= NXX6dnVZW0GQR1XS
SW48 M4XnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnMTWM2OD1zNz63O|E3KM7:TR?= Mn\LV2FPT0WU
HuP-T4 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF6LkCyNFYh|ryP NVizW5hoW0GQR1XS
NCI-H720 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF6LkG0NFIh|ryP NYDnWHBCW0GQR1XS
RCC10RGB M4Hp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDyT25VUUN3ME2xPE4yPjl5IN88US=> MXLTRW5ITVJ?
HD-MY-Z MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF6LkKyOVQh|ryP NYfwPG1DW0GQR1XS
A427 M2TMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXOTWM2OD1zOD61NFk1KM7:TR?= MVnTRW5ITVJ?
HCC2998 NI\OOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL2W3RKSzVyPUG4MlYxPTFizszN MWfTRW5ITVJ?
EPLC-272H MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF7LkC0N|Qh|ryP NFzUe3FUSU6JRWK=
C32 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF7LkC0OUDPxE1? MU\TRW5ITVJ?
UMC-11 NHL3eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfRTWM2OD1zOT6yNVI{KM7:TR?= NWDncW1pW0GQR1XS
CaR-1 M2DpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzKTWM2OD1zOT62PFA1KM7:TR?= NWfDTY5pW0GQR1XS
KYSE-410 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HldGlEPTB;MUmuPVE{QSEQvF2= NH2yfYRUSU6JRWK=
HuCCT1 NX;FZlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Xe3NWUUN3ME2yNE43Ojl2IN88US=> M3zNe3NCVkeHUh?=
LB996-RCC MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjteHVKSzVyPUKwMlcyPjhizszN MVvTRW5ITVJ?
KYSE-70 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fTWGlEPTB;MkCuPFA2QSEQvF2= MXzTRW5ITVJ?
CAL-72 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPYTWM2OD1{MD65NVUh|ryP MV3TRW5ITVJ?
Capan-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVNnRKSzVyPUKxMlA1OTNizszN M2q5VHNCVkeHUh?=
PANC-08-13 NFno[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\1TWM2OD1{MT6yOVE2KM7:TR?= MXzTRW5ITVJ?
SBC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBc3JKSzVyPUKxMlMxQDFizszN MYfTRW5ITVJ?
MFM-223 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfDV4pKSzVyPUKxMlM{PDJizszN NVni[WhYW0GQR1XS
BB49-HNC NUL2cHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrBTWM2OD1{MT61O|E3KM7:TR?= MmjCV2FPT0WU
SH-4 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fqN2lEPTB;MkGuOlYyQCEQvF2= NIfhbHdUSU6JRWK=
HuO9 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjvT5Q2UUN3ME2yNU46QDJ3IN88US=> MnLmV2FPT0WU
AM-38 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD6[FJSUUN3ME2yNk4xPDh3IN88US=> MXzTRW5ITVJ?
A431 NH;VTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvtNYVDUUN3ME2yN{4zOTF7IN88US=> MX\TRW5ITVJ?
YAPC M3;VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDEfIlKSzVyPUKzMlI3PTFizszN NX7UOHJzW0GQR1XS
LU-139 M3vKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfKTWVjUUN3ME2yN{41QDB7IN88US=> NGf6fXFUSU6JRWK=
HEC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ|LkS5N|ch|ryP MmHUV2FPT0WU
SCC-25 NF61d|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n1fWlEPTB;MkSuN|AxPiEQvF2= MkHOV2FPT0WU
HT-29 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLLN4k4UUN3ME2yOE4{QDJ|IN88US=> M{\lSXNCVkeHUh?=
PC-14 NF;iW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLz[3VMUUN3ME2yOE43PTdzIN88US=> NX;EfoNJW0GQR1XS
Calu-6 M{LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ3LkWwO|Eh|ryP MmXCV2FPT0WU
SJRH30 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILBTG9KSzVyPUK1MlY1QTZizszN NFzaXXlUSU6JRWK=
ChaGo-K-1 NWrmcWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy1d5ZKSzVyPUK2MlE3OjlizszN M3jCfnNCVkeHUh?=
IA-LM MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jQdWlEPTB;Mk[uN|Y1PSEQvF2= MlPlV2FPT0WU
GP5d NGniTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHRN3ZKSzVyPUK2MlQ1QTFizszN NETObIpUSU6JRWK=
NCI-H2291 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:4RnBqUUN3ME2yOk43PTRzIN88US=> MVrTRW5ITVJ?
BALL-1 M13QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rISWlEPTB;Mk[uPVM6PyEQvF2= NELmfFdUSU6JRWK=
HCC1954 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXLZ5VKSzVyPUK2Mlk5ODhizszN MWPTRW5ITVJ?
NCI-H2452 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X2cmlEPTB;MkeuOFE3OyEQvF2= NYrDNGx{W0GQR1XS
LU-99A MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ5LkW1PFIh|ryP NIrj[49USU6JRWK=
NTERA-S-cl-D1 NUjjVGxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfGd|dKSzVyPUK3MlczQTlizszN MVLTRW5ITVJ?
PANC-10-05 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe3TWM2OD1{Nz63O|c2KM7:TR?= M4rlSnNCVkeHUh?=
NCI-H2405 NUnrO49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\jPWdUUUN3ME2yO{46Ozh5IN88US=> MWrTRW5ITVJ?
MDA-MB-415 MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24ZlE6UUN3ME2yPE41OTN5IN88US=> MoTKV2FPT0WU
NCI-H2342 NVHF[nhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrUPHRzUUN3ME2yPE42OjhzIN88US=> MVzTRW5ITVJ?
TGBC24TKB NWq2S4d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm0NnJOUUN3ME2yPE44OTF5IN88US=> Ml:2V2FPT0WU
LU-134-A M1m3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ6LkmyOlEh|ryP MofxV2FPT0WU
SCC-4 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNzLkC0PVQh|ryP MXvTRW5ITVJ?
Saos-2 NEnJSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNzLkmzNFYh|ryP MXjTRW5ITVJ?
RERF-LC-MS M3jlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnDRVFTUUN3ME2zNk45OjNzIN88US=> NWTJPFg3W0GQR1XS
M14 NF7NUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rESWlEPTB;M{KuPVc3PCEQvF2= NU\rcINEW0GQR1XS
HPAF-II MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXMcpBoUUN3ME2zN{42ODFzIN88US=> NV[wTpdOW0GQR1XS
NCI-H1755 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q3TmlEPTB;M{SuN|MxPSEQvF2= NEnSVVhUSU6JRWK=
D-392MG M3zISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXVNZM4UUN3ME2zOU45Pjd2IN88US=> NVfrdJQ2W0GQR1XS
A704 M2n3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN4LkC0Nlch|ryP MYnTRW5ITVJ?
CP50-MEL-B MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7yNWs5UUN3ME2zOk4yQTFzIN88US=> M4PIUnNCVkeHUh?=
EW-18 NWH5TJUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj5dXRUUUN3ME2zOk41PTJizszN M4GxRXNCVkeHUh?=
WM-115 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\6TWM2OD1|Nj64NFk6KM7:TR?= NHO5PW5USU6JRWK=
LU-65 NUTQNXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli0TWM2OD1|Nz6xOFE4KM7:TR?= M1nHb3NCVkeHUh?=
NCI-H1563 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCxTWM2OD1|Nz6yOFg1KM7:TR?= NXvvfVVmW0GQR1XS
DBTRG-05MG NUXlPIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN6LkC2PVEh|ryP M1T0ZnNCVkeHUh?=
NCI-H630 M3u4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO2Rnc{UUN3ME2zPE41PzF2IN88US=> M331XXNCVkeHUh?=
NCI-H1155 M2DJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:xOm5KSzVyPUO5MlI1OiEQvF2= NXnnVFZWW0GQR1XS
OVACR-3 NUfj[ZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN7LkmxPVUh|ryP NILPeldUSU6JRWK=
OAW-42 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi2NJlqUUN3ME20NE41OjV6IN88US=> MnnpV2FPT0WU
JVM-2 M2LKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRzLkK0NVUh|ryP MYDTRW5ITVJ?
C3A MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTEU|VHUUN3ME20NU4{PDR5IN88US=> M3fUd3NCVkeHUh?=
HT55 NV\H[2ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLVTWM2OD12Mj6yPFQyKM7:TR?= Mn71V2FPT0WU
OVCAR-4 NE\WWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu1TWM2OD12Mj6yPVc1KM7:TR?= NFHlXYJUSU6JRWK=
MEG-01 NHqxfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTR{LkS2NVYh|ryP NILCeWZUSU6JRWK=
NCI-H82 NFXkd5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fSRWlEPTB;NEOuPVg6OiEQvF2= NYXtelJIW0GQR1XS
JEG-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTR2Lkm0O{DPxE1? MYTTRW5ITVJ?
BPH-1 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\5WXVGUUN3ME20Ok4{QTl6IN88US=> NGfmR25USU6JRWK=
MPP-89 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorkTWM2OD12Nz6yPFk5KM7:TR?= NEGydWpUSU6JRWK=
ALL-PO MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHme3VKSzVyPUS3MlQyQDhizszN MljBV2FPT0WU
HT NYnSZYJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\HNmlEPTB;NEeuOFkzKM7:TR?= NFvwU|RUSU6JRWK=
NCI-H2347 NH;WfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTR6LkC3NVUh|ryP MnXwV2FPT0WU
A2780 NGrRNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe2RoZ{UUN3ME20PU41OjJ6IN88US=> MkDDV2FPT0WU
KARPAS-299 NIfoPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTR7LkWxNVkh|ryP M1;EUnNCVkeHUh?=
NCI-H1651 NUPwd2Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjXWII5UUN3ME20PU45QDJzIN88US=> M4HsUnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 150 mg/kg PD 0332991处理 MDA-MB-435移植瘤完全抑制肿瘤。在多种人类肿瘤移植瘤中,PD 0332991也显示广谱抗癌活性,通过除去血管中p-Rb和增殖Marker Ki-67,且调节基因使其处于E2F转录水平控制。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Cdk实验:

PD0332991溶解在DMSO中。在96孔板上进行CDK 实验。通过杆状病毒感染,所有的CDK-cyclin 激酶复合体 在昆虫细胞中表达。实验底物为与GST融合的一段pRb。每孔体积为0.1 ml,包含:终浓度为20 mm Tris-HCl(pH 为7.4), 50 mmNaCl, 1 mm二硫苏糖醇, 10 mmMgCl2, 25 μm ATP (用于CDK4-cyclin D1, CDK6-cyclin D2,和CDK6-cyclin D3)或12 μm ATP (用于CDK2-cyclin E, CDK2-cyclin A, 和CDC2-cyclin B),0.25 μCi [γ-32P]ATP, 20 ng 酶, 1 μg GST·RB-Cterm, 及PD 0332991 (0.001-0.1μM)。除了[γ-32P]ATP的所有混合物加到孔中,放在搅拌器上搅拌2分钟。加入 [γ-32P]ATP开始反应, 在25 oC下温育15分钟。加入0.1 ml 20% 三氯乙酸终止反应, 在4 oC维持至少1小时,使底物沉淀。用0.2 ml 10%三氯乙酸冲洗5次,用β-计数器板测定掺入的放射性。
细胞实验:

[1]

+ 展开
  • Cell lines: MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,和K562细胞
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24小时
  • Method:

    肿瘤细胞包括MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM,及K562按每孔2×104个细胞接种在96孔板上,温育过夜。加入PD 0332991 (0.01-1 μM) ,37oC温育24小时。每孔加入[14C]胸甘(0.1 μCi) ,进行同位素示踪,持续72小时。用β-计数器板测定掺入的放射性。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带晚期人类肿瘤移植瘤,包括结肠-205, MDA-MB-435 乳腺癌, SF-295 恶性胶质瘤, ZR-75-1 乳腺癌, PC-3 前列腺癌, H125 肺癌, SW-620结肠癌, H23肺癌,及MDA-MB-468 乳腺癌 (Rb 阴性)的SCID鼠
  • Formulation: 溶解在乳酸钠buffer(50 mM, pH 4.0)中
  • Dosages: 0-150 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
6 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 483.99
化学式

C24H29N7O2.HCl

CAS号 827022-32-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

相关CDK产品

Tags: 购买Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl供应商 | 采购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl价格 | Palbociclib (PD-0332991) HCl生产 | 订购Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID